Sexually transmitted infections · 2026
Evaluation of the diagnostic performance of the Eazyplex platform for detection of Chlamydia trachomatis and Neisseria gonorrhoeae among women in Zimbabwe.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Majaha Moira, Mwaturura Tinashe, Machinga Farai, Samatanga Brighton, Kranzer Katharina, Dziva Chikwari Chido
Аннотация
BACKGROUND: Gaps in sexually transmitted infection (STI) diagnosis hinder effective STI control particularly in low-resource settings where syndromic management is often the standard of care. Rapid and affordable point-of-care (POC) diagnostics for STIs such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are needed. This study evaluated the diagnostic performance of Eazyplex (a point-of-care test (POCT)) to screen CT and NG among sexually active women in Zimbabwe.
METHODS: We enrolled 220 sexually active women aged 18-35 (median 28 years) years attending a family planning clinic in Zimbabwe. Samples collected from vaginal swabs were tested for CT and NG using Eazyplex, GeneXpert and PRESTO CT/NG. Diagnostic performance metrics (sensitivity, specificity, positive predictive value and negative predictive value) were calculated against GeneXpert, PRESTO CT/NG and a GeneXpert+PRESTO CT/NG combined reference standard. For the combined reference standard, a participant was categorised as having a positive result for CT or NG if either of the two tests yielded a positive result.
RESULTS: Overall, Eazyplex reported high specificity and low sensitivity. CT results demonstrated sensitivities of 60.9%, 76.2% and 64.0% compared with GeneXpert, PRESTO CT/NG and GeneXpert+PRESTO CT/NG combined, respectively. NG results demonstrated sensitivities of 57.1%, 66.7% and 66.7% compared with GeneXpert, PRESTO CT/NG and GeneXpert+PRESTO CT/NG combined, respectively. All results had specificity ≥98.5%.
CONCLUSION: Eazyplex was highly specific but moderately sensitive in detecting NG and CT. While not suitable as a standalone screening tool, its rapid turnaround gives it potential for use as near POCT in low-resource settings.
METHODS: We enrolled 220 sexually active women aged 18-35 (median 28 years) years attending a family planning clinic in Zimbabwe. Samples collected from vaginal swabs were tested for CT and NG using Eazyplex, GeneXpert and PRESTO CT/NG. Diagnostic performance metrics (sensitivity, specificity, positive predictive value and negative predictive value) were calculated against GeneXpert, PRESTO CT/NG and a GeneXpert+PRESTO CT/NG combined reference standard. For the combined reference standard, a participant was categorised as having a positive result for CT or NG if either of the two tests yielded a positive result.
RESULTS: Overall, Eazyplex reported high specificity and low sensitivity. CT results demonstrated sensitivities of 60.9%, 76.2% and 64.0% compared with GeneXpert, PRESTO CT/NG and GeneXpert+PRESTO CT/NG combined, respectively. NG results demonstrated sensitivities of 57.1%, 66.7% and 66.7% compared with GeneXpert, PRESTO CT/NG and GeneXpert+PRESTO CT/NG combined, respectively. All results had specificity ≥98.5%.
CONCLUSION: Eazyplex was highly specific but moderately sensitive in detecting NG and CT. While not suitable as a standalone screening tool, its rapid turnaround gives it potential for use as near POCT in low-resource settings.